From our Annual Public Meeting to topic-specific convenings, the Reagan-Udall Foundation for the FDA brings stakeholders together on matters critical to regulatory science and practice. These events, often hosted at the request of FDA leadership, provide space for expert analysis and candid discussion on FDA’s priority issues. See below for upcoming events.

Past Events

FDA Commissioner Previews OND Changes at Annual Meeting
Dr.
IMEDS Panel Presentation at DIA Global Annual Meeting 2018
Stop by booth #622 to learn more about the Foundation and our programs including, Innovation in Medical Evidence Development and Surveillance (IMEDS), the Expanded Access Navigator, and ou
Pre-approval Access Webinar
The Reagan-Udall Foundation for the FDA's Executive Director, June Wasser, was a presenter on a June 6th webinar sponsored by Johnson & Johnson and NYU Langone Health.
Panel of Commissioners Discuss Evolution of FDA at Foundation's Public Meeting May 4th
Each year the Foundation conducts an annual meeting, open to the public, to discuss its activities and how it supports FDA.
2018 Annual Public Meeting
We have reached room capacity so registration to attend the meeting is now closed.
Press release on Expanded Access Navigator after "right-to-try" vote
DATELINE: WASHINGTON D.C. - MARCH 22, 2018 Right-To-Try law not a shortcut to investigational drugs – Expanded Access Navigator can reduce confusion.
Navigator presentation at CBI's Expanded Access Programs 2018
Executive Director June Wasser's talk on the Evolving Scope of the Expanded Access Navigator starts at 11am, Wednesday March 28th and includes an update on its expansion into rare diseases.
Rare Disease Day at NIH
Stop by the foundation's table at NIH's Rare Disease Day on March 1st for a demonstration of the Expanded Access Navigator.
FDA News Picks Up on Foundation Fellowships as Workforce Multiplier
FDA hopes to bolster its scientific staff in 2018 and this piece in FDA News explains how the Reagan-Uda
Sentinel workshop and next-day training
New analytic tools and methods enhancements have unlocked access to more diverse sources of data than ever before, improving the quality of evidence for safety surveillance.